BioSpace News Archive

BioXcel Therapeutics, Inc. today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will present corporate updates and plans for 2022 at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually, on Thursday, January 13, 2022 at 9:45 a.m.

First Wave BioPharma, Inc., announced that President and Chief Executive Officer James Sapirstein will participate in the Longwood Healthcare Leaders Conference and H.C. Wainwright BioConnect 2022.

CareDx, Inc. today announced a partnership with the International Society for Heart and Lung Transplantation (ISHLT) in offering an Innovation Challenge Award to clinicians to further AlloSure® and AlloMap® research.

PharmaTher Holdings Ltd. today announced the publication of a scientific article demonstrating the potential of KETABET™ to prevent the potential adverse psychiatric effects of repeated ketamine treatment for depression and other indications including suicidal ideation, substance abuse, post-traumatic stress disorder, and chronic pain.

Cullinan Oncology, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Therapy Designation for CLN-081 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.

Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference.

Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference.

Acorda Therapeutics, Inc. announced that Ron Cohen, MD, President and CEO, will present at the H.C. Wainwright BIOCONNECT Virtual Conference, taking place from January 10 – 13, 2022.

Apollomics Inc. today announced that Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of Apollomics, was recently appointed to Chairman of the Board for the BayHelix Group, effective January 2022.

AVROBIO, Inc. today announced that it is shifting its portfolio priorities to focus on other clinical-stage programs and extending its cash runway into the first quarter of 2024.